Skip to content

News and Events

#

All News and Events

Mar 18, 2024
#

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial in "The Lancet Neurology Journal"

Data published in The Lancet Neurology showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopa
Apr 10, 2023
#

World Parkinson’s Day (WPD) - April 11th 2023

The first World Parkinson's Day (WPD) was held in 1997. The date commemorates the birthday of Dr James Parkinson, born 11 April 1755,
Jan 09, 2023
#

Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson’s Disease Patients with Motor Fluctuations

The results confirm the potential of ND0612 as an effective, safe, and well-tolerated treatment option to better control motor fluctuations
Apr 10, 2022
#

Parkinson's Awareness Month | April 2022 | Join the National Conference

The Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease – a Tel Aviv University affiliate – in collaboration with the Israel Parkinson Association, will hold this year's National Conference on Parkinson's Disease on Monday, April 11.
Apr 04, 2022
#

BeyoND phase 2b data indicates ND0612 has a positive long-term safety profile for people with Parkinson’s Disease

NeuroDerm presents data at 2022 American Academy of Neurology Annual Meeting
Mar 16, 2022
#

Parkinson’s Unity Walk is back in New York City’s Central Park on April 23rd, 2022

After two years of virtual celebrations, the Parkinson's Unity Walk (PUW) is back in New York City’s Central Park on April 23rd, 2022
Sep 24, 2021
#

ND0612 for Parkinson’s Disease – Global Phase 2b Study Data Published in Journal Movement Disorders and at MDS 2021 Conference

We are proud to announce that Movement Disorders Journal published the one-year safety data of ND0612 from the global Phase 2b study (BeyoND) in people with Parkinson’s Disease (PD) experiencing motor fluctuations
May 30, 2021
#

The annual Brainstorming for Parkinson’s Disease (BSPD) meeting

We are proud to have sponsored the annual Brainstorming for Parkinson’s Disease (BSPD) meeting, where we also presented our latest updates.
May 30, 2021
#

The Tikvah for Parkinson Wellness Retreat

We are proud to be the only industry sponsor of an intimate retreat for people with Parkinson’s and their partners, organized by Tikvah for Parkinson.
Apr 30, 2021
#

The first virtual Aufzien conference, 30 April 2021

The online Aufzien conference, sponsored by NeuroDerm and others, was attended by an astounding number of over 1,000 participants, most of whom are people living with PD and their partners.
Sep 14, 2020
#

NeuroDerm and MTPC announce new presentation at the MDS 2020 Congress

NeuroDerm and Mitsubishi Tanabe Pharma announce presentation of long-term safety of levodopa/carbidopa infusion with ND0612 at the International Congress of Parkinson’s Disease and Movement Disorders
Aug 28, 2019
#

Phase 3 of ND0612 clinical trial Initiated in the United States for Parkinson's disease with motor fluctuations

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the initiation of the Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatment, compared to oral immediate-release carbidopa/levodopa (CD/LD) in people with Parkinson’s disease (PD) experiencing motor fluctuations.

Let's Stay in Touch

For general inquiries or to learn more about NeuroDerm, please complete the form below. For medical information or to report on your own health or experience, please consult your healthcare provider. Please click here for information about our clinical trials.

*
*
*
*